Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Escalating Multiple Dose Study to Evaluate the Safety, Toxicity, Pharmacokinetics, and Preliminary Activity of BTX-1188 in Subjects With Advanced Malignancies

Next Previous
Trial Profile

An Open Label, Escalating Multiple Dose Study to Evaluate the Safety, Toxicity, Pharmacokinetics, and Preliminary Activity of BTX-1188 in Subjects With Advanced Malignancies

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 20 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BTX 1188 (Primary)
  • Indications Acute myeloid leukaemia; Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors BioTheryX

Most Recent Events

  • 14 Sep 2023 Status changed from recruiting to discontinued.
  • 26 Jan 2022 According to a BioTheryX media release, first patient has been dosed in this trial.
  • 26 Jan 2022 Status changed from not yet recruiting to recruiting, according to a BioTheryX media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top